Nucor earnings beat by $0.08, revenue fell short of estimates
NEW YORK - IN8bio, Inc. (NASDAQ:INAB), a biopharmaceutical firm specializing in gamma-delta T cell therapies, has reported positive Phase 1 trial outcomes for its INB-200 treatment for newly diagnosed glioblastoma multiforme (GBM). The study data, presented at the American Society of Clinical Oncology Annual Meeting on May 30, 2025, showed a median progression-free survival (mPFS) of 16.1 months, significantly exceeding the 6.9 months typically seen with the standard Stupp protocol. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 4.3x and more cash than debt on its balance sheet, though it’s currently experiencing rapid cash burn.
Patients treated with INB-200 experienced no serious toxicities beyond those associated with chemotherapy, and no cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) were observed. Four trial participants have remained alive and progression-free for over two years, with some able to return to work.
The company’s Drug Resistant Immunotherapy (DRI) employs genetically modified gamma-delta T cells delivered directly into the brain to potentially improve survival rates. This approach aims to target chemo-resistant cancer cells that often lead to relapse. The trial results are notable as a 2 to 3 month improvement in mPFS is typically considered significant by the FDA.
IN8bio’s Phase 2 trial of INB-400 in GBM patients is also underway, with preliminary mPFS at 10.8 months. Further updates are anticipated later in 2025.
The company will host a conference call with Dr. Burt Nabors, the Principal Investigator, today to discuss the clinical data. IN8bio aims to extend patient survival and improve quality of life with its gamma-delta T cell therapies, potentially offering a novel treatment pathway for solid tumor cancers like GBM. Trading at $0.15 per share, the stock has seen a significant decline of about 88% over the past year, though InvestingPro analysis suggests the company is currently undervalued. Analysts maintain an optimistic outlook with price targets ranging from $1.20 to $7.50 per share.
These findings are based on a press release statement and have not been independently verified. Further studies and regulatory approval will be required to confirm the efficacy and safety of INB-200 for the treatment of GBM. For deeper insights into IN8bio’s financial health and growth prospects, including 8 additional ProTips and comprehensive financial metrics, visit InvestingPro.
In other recent news, IN8bio has presented promising preclinical data for its INB-619 program, which targets CD-19 in the treatment of lupus. The findings suggest INB-619 can effectively eliminate harmful B cells without causing severe inflammatory side effects, marking a potential breakthrough in autoimmune disease treatment. Additionally, H.C. Wainwright maintained its Buy rating for IN8bio but adjusted the stock price target from $8.00 to $6.00, citing the impact of a recent capital raise. The firm continues to express confidence in IN8bio’s long-term potential despite the revised target. Furthermore, IN8bio announced the resignation of board member Travis Whitfill, effective May 9, 2025, with no disagreements cited regarding company operations. The company has not disclosed a successor or any immediate changes in governance following Whitfill’s departure. These developments come as IN8bio continues to advance its γδ T-cell engager platform for cancer and autoimmune diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.